Bringing the fundamentals into focus…
Back to Intellia Therapeutics, Inc.
How Intellia Therapeutics, Inc. stacks up
NTLA · against 398 other Healthcare companies of similar size
Growth
66/ 100
Above the middle of the pack.
Ranked #135 of 399 · scores higher than 65% of peers
Bars: peers in each 10-point band of the growth score50 peers with a growth score of 60–69, including NTLA · Click a bar to see the companies
Why growth scores 66?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its revenue growth, which is stronger than most Healthcare peers.
- Earnings per share growth is not reported, so it is left out of the score.
- 3-year revenue growth is close to the peer norm. 3-year revenue growth: 9.1% vs peer median 5.8%
- faster revenue growth over the last year: stronger than 75% of peers. Revenue growth: 16.9% vs peer median 6.1%
Metric by metric
Position: dot = NTLA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | NTLA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 402 reported | 16.9% | 6.3% | 74% | 33% | |
| Earnings per share growthHigher is better · 221 reported | Not reported | 10.0% | — | — | 33% |
| 3-year revenue growthHigher is better · 391 reported | 9.1% | 7.1% | 55% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around NTLA| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 1 | 1.4B USD | 99 | 73 | |
| 1 | 27.6B SEK (≈$2.8B) | 99 | 76 | |
| 1 | 2.1B USD | 99 | 96 | |
| 1 | 2.8B USD | 99 | 51 | |
| 135 | 9.3B CNY (≈$1.3B) | 66 | 56 | |
| 135 | 6.8B HKD (≈$872M) | 66 | 78 | |
| 135 | 8.3B CNY (≈$1.2B) | 66 | 66 | |
| 135 | 1.7B USD | 66 | 30 | |
| 135 | 1.7B USD | 66 | 33 | |
| 140 | 225.8B JPY (≈$1.5B) | 65 | 69 | |
| 140 | 1.2B USD | 65 | 42 | |
| 140 | 2.9B USD | 65 | 44 | |
| 140 | 179.7B INR (≈$2.2B) | 65 | 74 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score